PMID- 12204533
OWN - NLM
STAT- MEDLINE
DCOM- 20030515
LR  - 20220223
IS  - 1535-6108 (Print)
IS  - 1535-6108 (Linking)
VI  - 2
IP  - 2
DP  - 2002 Aug
TI  - Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor 
      growth.
PG  - 127-37
AB  - ErbB2 is a ligand-less member of the ErbB receptor family that functions as a 
      coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target 
      ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically 
      hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of 
      ligand-dependent ErbB2 signaling by 2C4 occurs in both low- and 
      high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive 
      tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated 
      ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of 
      several breast and prostate tumor models is inhibited by 2C4 treatment.
FAU - Agus, David B
AU  - Agus DB
AD  - Cedars-Sinai Prostate Cancer Center, Los Angeles, California 90048, USA.
FAU - Akita, Robert W
AU  - Akita RW
FAU - Fox, William D
AU  - Fox WD
FAU - Lewis, Gail D
AU  - Lewis GD
FAU - Higgins, Brian
AU  - Higgins B
FAU - Pisacane, Paul I
AU  - Pisacane PI
FAU - Lofgren, Julie A
AU  - Lofgren JA
FAU - Tindell, Charles
AU  - Tindell C
FAU - Evans, Douglas P
AU  - Evans DP
FAU - Maiese, Krista
AU  - Maiese K
FAU - Scher, Howard I
AU  - Scher HI
FAU - Sliwkowski, Mark X
AU  - Sliwkowski MX
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Androgens)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Ligands)
RN  - 0 (Neuregulin-1)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Receptor, ErbB-3)
SB  - IM
CON - Cancer Cell. 2002 Aug;2(2):93-5. PMID: 12204526
MH  - Androgens/metabolism
MH  - Animals
MH  - Antibodies, Monoclonal/immunology/*therapeutic use
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Breast Neoplasms/*drug therapy/metabolism/*pathology
MH  - Cell Division/drug effects
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Ligands
MH  - Male
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Neuregulin-1/pharmacology
MH  - Prostatic Neoplasms/*drug therapy/metabolism/*pathology
MH  - Protein Binding/drug effects
MH  - RNA, Messenger/genetics/metabolism
MH  - Receptor, ErbB-2/*antagonists & inhibitors/genetics/immunology/metabolism
MH  - Receptor, ErbB-3/metabolism
MH  - *Signal Transduction/drug effects
MH  - Time Factors
MH  - Transplantation, Heterologous
MH  - Tumor Cells, Cultured
EDAT- 2002/09/03 10:00
MHDA- 2003/05/16 05:00
CRDT- 2002/09/03 10:00
PHST- 2002/09/03 10:00 [pubmed]
PHST- 2003/05/16 05:00 [medline]
PHST- 2002/09/03 10:00 [entrez]
AID - S1535610802000971 [pii]
AID - 10.1016/s1535-6108(02)00097-1 [doi]
PST - ppublish
SO  - Cancer Cell. 2002 Aug;2(2):127-37. doi: 10.1016/s1535-6108(02)00097-1.